CLCS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 14:57):

Stats
Today's Volume	1 000.00
Average Volume	7 897.00
Market Cap	7 709.00
EPS	$-0.0350 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-03-10	Verstraete George	Buy	0
2021-08-09	Soave Darlene	Buy	800 000	Warrant (Option to buy)
2021-06-30	Zolty David	Buy	4 860	Common Stock
2021-06-30	Soave Darlene	Buy	59 507	Common Stock
2021-06-30	Brown Dennis M	Buy	2 976	Common Stock

INSIDER POWER
0.00
Last 47 transactions
Buy: 4 869 574 \| Sell: 6 627 844

Cell Source, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cell Source, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.150

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.150

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-188.06

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.190

Financial Reports:

No articles found.

Cell Source, Inc.

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.